礼来将以24亿美元收购生物科技公司Orna Therapeutics

Group 1 - The core viewpoint of the article is that Eli Lilly announced its intention to acquire biotechnology company Orna Therapeutics for up to $2.4 billion in cash to strengthen its position in the autoimmune sector [1] Group 2 - Orna Therapeutics' main candidate drug, ORN-252, is aimed at treating B cell-driven autoimmune diseases and is currently in the early stages of development [1]